# Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy

> **NCT03982121** · PHASE1 · WITHDRAWN · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris**

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** FOLFOX regimen
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** GLA-SE

## Key facts

- **NCT ID:** NCT03982121
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-06-04
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never began because of withdrawal of the industrial partner
- **Last updated:** 2020-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03982121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03982121, "Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03982121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*